Atypical PKC: therapeutic target for Alzheimer's?

Robert V Farese^{1

2}, Mini P Sajan^{1

2}

Affiliations

¹ Division of Endocrinology and Metabolism, Department of Internal Medicine, University of South Florida, College of Medicine, Tampa, FL 33612, USA.
² James A. Haley Veterans Administration Medical Center, Tampa, FL 33612, USA.

Editorial

Robert V Farese et al. Aging (Albany NY). 2018.

. 2018 Dec 20;11(1):13-14.

doi: 10.18632/aging.101730.

Robert V Farese^{1

2}, Mini P Sajan^{1

2}

¹ Division of Endocrinology and Metabolism, Department of Internal Medicine, University of South Florida, College of Medicine, Tampa, FL 33612, USA.
² James A. Haley Veterans Administration Medical Center, Tampa, FL 33612, USA.

No abstract available

Keywords: Abeta; Alzheimer's disease; atypical PKC; beta-secretase; phospho-tau.

References

1. Cole SL, Vassar R. Mol Neurodegener. 2007; 2:22. 10.1186/1750-1326-2-22 - DOI - PMC - PubMed
1. Sajan M, et al. Diabetes. 2016; 65:1892–903. 10.2337/db15-1428 - DOI - PMC - PubMed
1. Sajan MP, et al. Neurobiol Aging. 2018; 61:225–37. 10.1016/j.neurobiolaging.2017.09.001 - DOI - PMC - PubMed
1. Talbot K, et al. J Clin Invest. 2012; 122:1316–38. 10.1172/JCI59903 - DOI - PMC - PubMed
1. Craft S, et al. J Alzheimers Dis. 2017; 57:1325–34. 10.3233/JAD-161256 - DOI - PMC - PubMed